India bans sale and manufacturing of tobacco products.

Sep.06.2022
India bans sale and manufacturing of tobacco products.
India's health ministry bans the sale and use of all tobacco and nicotine products under the Food Safety and Standards Act.

The Ministry of Health has announced a complete ban on the sale, manufacturing, distribution, or use of all tobacco and nicotine-containing products, including Gutkha, Pan Masala, Chhap Tobacco, Pure Tobacco, Kaini, Zarda, and Flavoured and flavoured tobacco, in accordance with the Food Safety and Standards Act of 2006, to protect public interest.


In a notice, V Vumlumang, the Food Safety Commissioner and Deputy Secretary General for Health and FW, stated that products containing tobacco and nicotine are harmful to human health. In accordance with regulations from the 2011 "Food Safety and Standards (Prohibition and Restriction on Sales) Act," the sale of consumer products containing tobacco and nicotine as ingredients is prohibited.


In a recent ruling, India's Supreme Court stated that manufacturers are selling a product called pan masala (tobacco-free chewable tobacco) packaged in separate small packets with added spices in order to circumvent a ban on the sale of gutka. However, these products are typically sold together by the same supplier from the same place, allowing consumers to purchase both pan masala and spicy chewable tobacco and mix them together for consumption.


Therefore, the Supreme Court has instructed relevant legal institutions to comply with the legal authorization of the Food Safety and Standards (Prohibition and Restriction of Sales) Regulation 2.3.4 in 2011, and has directed all state and federal territory health ministers to ensure full compliance with the ban on the manufacture and sale of gutkha and pan masala containing tobacco and/or nicotine.


He reported that in order to protect public health, Manipur would ban the manufacture, storage, distribution, or sale of gutka and pan masala for a period of one year.


Statement


This article is compiled from third-party information and is intended for industry exchange and learning purposes only.


This article does not represent the views of 2FIRSTS, and 2FIRSTS is unable to confirm the authenticity and accuracy of the article's contents. The translation of this article is only intended for internal industry research and communication purposes.


Due to the limitations in translation proficiency, the translated article may not fully express the original text. Please refer to the original article for accuracy.


2FIRSTS maintains complete alignment with the Chinese government on any domestic, Hong Kong, Macao, Taiwan, and foreign statements and positions.


Copyright of compiled information belongs to the original media and authors. If infringement occurs, please contact for deletion.


This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

Imperial Brands FY25 Results: NGP Net Revenue Up 13.7%, Americas Surges Nearly 70%
Imperial Brands FY25 Results: NGP Net Revenue Up 13.7%, Americas Surges Nearly 70%
Imperial Brands reported FY25 NGP net revenue of £368 million, up 13.7% at constant currency. Growth in the Americas accelerated sharply, with NGP revenue up 69.8%, driven by the expansion of the modern oral brand Zone. Europe delivered 8.8% growth, supported by blu’s double-digit vapour share across key markets. Adjusted NGP operating losses narrowed to £76 million, putting the category closer to breakeven.
Nov.18 by 2FIRSTS.ai
WHO Chief Warns of E-Cigarette Threat to Youth as COP11 Opens in Geneva
WHO Chief Warns of E-Cigarette Threat to Youth as COP11 Opens in Geneva
More than 1,400 delegates from 162 Parties convened in Geneva on November 17 for the Eleventh Session of the Conference of the Parties (COP11) to the WHO Framework Convention on Tobacco Control (WHO FCTC). WHO Director-General Tedros Adhanom Ghebreyesus opened the session with a stark warning: tobacco and nicotine companies are targeting schools as the “new front line” to recruit a generation of addicts through e-cigarettes and nicotine pouches.
Nov.18 by 2FIRSTS.ai
Australia TGA Warns Delivery Platforms: Don’t Promote or Supply Vapes Illegally
Australia TGA Warns Delivery Platforms: Don’t Promote or Supply Vapes Illegally
The Therapeutic Goods Administration (TGA) warned online delivery platforms not to breach Australian vape laws and said it worked with two major companies to remove non-compliant material. Under the Therapeutic Goods Act 1989, advertising vapes to the public is banned and sales are pharmacy-only; tobacconists and convenience stores cannot supply vapes. TGA will continue enforcement, with severe penalties for breaches.
Oct.30 by 2FIRSTS.ai
Leaked EU Paper Suggests COP11 Push to Ban Nicotine Pouches and Flavoured Nicotine Products
Leaked EU Paper Suggests COP11 Push to Ban Nicotine Pouches and Flavoured Nicotine Products
According to media reports, a leaked European Commission document indicates the EU plans to push for its strictest regulatory framework on nicotine and tobacco products at COP11 in Switzerland this November, including measures such as a full ban on nicotine pouches and flavoured products.
Oct.10 by 2FIRSTS.ai
Altria’s Nicotine Pouch Rollout in the U.S.: On! PLUS May Launch on October 14, Not Yet FDA-Approved
Altria’s Nicotine Pouch Rollout in the U.S.: On! PLUS May Launch on October 14, Not Yet FDA-Approved
Altria’s new nicotine pouch On! PLUS™ is slated to launch in the U.S. on October 14, debuting in North Carolina, Texas, and Florida. The product uses NICOSILK™ technology and will offer multiple nicotine strengths. FDA approval has not yet been granted, but Helix says it is proceeding in line with compliance requirements.
Oct.11 by 2FIRSTS.ai
HSSP INTL signs agreement with COTY to expand e-cigarette business in Middle East and Australia
HSSP INTL signs agreement with COTY to expand e-cigarette business in Middle East and Australia
HSSP INTL(03626.HK) partners with COTY to establish e-cigarette venture in UAE, expand distribution of Heaven Gifts brand.
Oct.30 by 2FIRSTS.ai